Singapore markets closed

Straits Times Index
3,292.93
-3.96(-0.12%)
Nikkei
38,236.07
-37.98(-0.10%)
Hang Seng
18,475.92
+268.79(+1.48%)
FTSE 100
8,213.49
+41.34(+0.51%)
Bitcoin USD
63,623.11
+1,975.30(+3.20%)
CMC Crypto 200
1,359.39
+82.41(+6.45%)

DGX Dec 2024 130.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

18.49

0.00

(0.00%)

At close: 01:00PM EDT

Zacks
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.
Zacks
Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics
Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.
PR Newswire
Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.